FR19C1046I1 - (+)-2-[1-(3-éthoxy-4-méthoxyphényl)-2-méthylsulfonyléthyl]-4-acétylaminoisoindoline-1,3-dione: ses procédés d'utilisation et compositions correspondantes - Google Patents

(+)-2-[1-(3-éthoxy-4-méthoxyphényl)-2-méthylsulfonyléthyl]-4-acétylaminoisoindoline-1,3-dione: ses procédés d'utilisation et compositions correspondantes

Info

Publication number: FR19C1046I1
Authority: FR; France
Prior art keywords: acetylaminoisoindoline; methylsulfonylethyl; dione; methoxyphenyl; ethoxy
Prior art date: 2002-03-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

Other languages

English (en)

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Celgene Corp

Original Assignee

Celgene Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-20

Filing date

2019-07-12

Publication date

2019-08-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28457137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR19C1046(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2019-07-12 Application filed by Celgene Corp filed Critical Celgene Corp

2019-08-09 Publication of FR19C1046I1 publication Critical patent/FR19C1046I1/fr

2022-07-08 Application granted granted Critical

2022-07-08 Publication of FR19C1046I2 publication Critical patent/FR19C1046I2/fr

Status Active legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Otolaryngology (AREA)
Hematology (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Psychiatry (AREA)
Gastroenterology & Hepatology (AREA)

FR19C1046C 2002-03-20 2019-07-12 (+)-2-[1-(3-éthoxy-4-méthoxyphényl)-2-méthylsulfonyléthyl]-4-acétylaminoisoindoline-1,3-dione: ses procédés d'utilisation et compositions correspondantes Active FR19C1046I2 (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US36651502P	2002-03-20	2002-03-20
US43845003P	2003-01-07	2003-01-07
EP03721414A EP1485087B1 (fr)	2002-03-20	2003-03-20	(+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione pour le traitement du psoriasis par administration orale
PCT/US2003/008738 WO2003080049A1 (fr)	2002-03-20	2003-03-20	(+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: leurs procedes d'utilisation et leurs compositions
EP09003138.6A EP2074995B1 (fr)	2002-03-20	2003-03-20	(+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: leurs procedes d'utilisation et leurs compositions

Publications (2)

Publication Number	Publication Date
FR19C1046I1 true FR19C1046I1 (fr)	2019-08-09
FR19C1046I2 FR19C1046I2 (fr)	2022-07-08

Family

ID=28457137

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR19C1046C Active FR19C1046I2 (fr)	2002-03-20	2019-07-12	(+)-2-[1-(3-éthoxy-4-méthoxyphényl)-2-méthylsulfonyléthyl]-4-acétylaminoisoindoline-1,3-dione: ses procédés d'utilisation et compositions correspondantes

Country Status (23)

Country	Link
US (14)	US6962940B2 (fr)
EP (9)	EP2311453B1 (fr)
JP (4)	JP2005525386A (fr)
KR (6)	KR101104991B1 (fr)
CN (2)	CN100427085C (fr)
AT (1)	ATE440599T1 (fr)
AU (1)	AU2003224729C1 (fr)
BE (1)	BE2019C008I2 (fr)
CA (2)	CA2479666C (fr)
CY (6)	CY1109380T1 (fr)
DE (1)	DE60328974D1 (fr)
DK (6)	DK2295055T3 (fr)
ES (8)	ES2595375T3 (fr)
FR (1)	FR19C1046I2 (fr)
HU (5)	HUE043539T2 (fr)
IL (3)	IL164147A0 (fr)
LU (1)	LUC00125I2 (fr)
MX (2)	MX366328B (fr)
NL (1)	NL300994I2 (fr)
NZ (1)	NZ535798A (fr)
PT (6)	PT2223687T (fr)
SI (5)	SI2295055T1 (fr)
WO (1)	WO2003080049A1 (fr)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SK17799A3 (en) *	1996-08-12	1999-11-08	Celgene Corp	Cyano and carboxy derivatives of substituted styrenes, pharmaceutical composition containing same and their use
US8030343B2 (en) *	2000-06-08	2011-10-04	Celgene Corporation	Pharmaceutically active isoindoline derivatives
US7276529B2 (en) *	2002-03-20	2007-10-02	Celgene Corporation	Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en)	2002-03-20	2005-11-08	Celgene Corporation	(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en)	2002-03-20	2011-02-22	Celgene Corporation	Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
CA2379887C (fr) *	2002-04-09	2004-01-20	Bernard Charles Sherman	Comprimes stables contenant de la simvastatine
WO2003097040A1 (fr) *	2002-05-17	2003-11-27	Celgene Corporation	Methodes et compositions mettant en oeuvre des medicaments selectifs inhibiteurs des cytokines pour le traitement et la prise en charge des cancers et autres maladies
US20100129363A1 (en) *	2002-05-17	2010-05-27	Zeldis Jerome B	Methods and compositions using pde4 inhibitors for the treatment and management of cancers
AU2003228509B2 (en) *	2002-10-15	2008-06-26	Celgene Corporation	Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
US20040087558A1 (en) *	2002-10-24	2004-05-06	Zeldis Jerome B.	Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20050203142A1 (en) *	2002-10-24	2005-09-15	Zeldis Jerome B.	Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US7776907B2 (en)	2002-10-31	2010-08-17	Celgene Corporation	Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
BR0316057A (pt)	2002-11-06	2005-09-20	Celgene Corp	Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
WO2004043336A2 (fr) *	2002-11-06	2004-05-27	Celgene Corporation	Methodes d'utilisation d'agents inhibiteurs selectifs de la cytokine et compositions comprenant ces agents pour le traitement et la gestion de maladies myeloproliferatives
WO2004045597A1 (fr) *	2002-11-18	2004-06-03	Celgene Corporation	Compositions comprenant un (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide et methodes d'utilisation de ces compositions
NZ540546A (en) *	2002-11-18	2008-03-28	Celgene Corp	Methods of using and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
US20040175382A1 (en) *	2003-03-06	2004-09-09	Schafer Peter H.	Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
EP1605935A4 (fr) *	2003-03-06	2009-05-20	Celgene Corp	Methodes d'utilisation et compositions comprenant des medicaments selectifs inhibitoires de cytokine pour le traitement et pour la gestion de troubles du systeme nerveux central
US20060205749A1 (en) *	2003-03-13	2006-09-14	Yuzuru Abe	Remedy and/or preventive for lung diseases
JP2007524656A (ja) *	2003-10-23	2007-08-30	セルジーン・コーポレーション	疼痛を治療、改変および管理するための選択的サイトカイン阻害薬を含む組成物ならびにその使用方法
US20050142104A1 (en) *	2003-11-06	2005-06-30	Zeldis Jerome B.	Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
KR20060124610A (ko) *	2003-11-06	2006-12-05	셀진 코포레이션	석면-관련된 질환 또는 장애를 치료 및 관리하기 위하여ｊｎｋ 억제제를 사용하는 방법 및 이 물질을 포함하는조성물
JPWO2005056009A1 (ja) *	2003-12-12	2007-07-05	協和醗酵工業株式会社	肺疾患治療剤
US20100173864A1 (en)	2004-03-29	2010-07-08	Cheng Jin Q	Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100009928A1 (en) *	2004-03-29	2010-01-14	Cheng Jin Q	Compositions including triciribine and taxanes and methods of use thereof
US20100009929A1 (en)	2004-03-29	2010-01-14	Cheng Jin Q	Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
CA2561513C (fr)	2004-03-29	2019-02-26	University Of South Florida	Traitement efficace des tumeurs et du cancer a l'aide de la triciribine et de composes associes
US20100028339A1 (en)	2004-03-29	2010-02-04	Cheng Jin Q	Compositions including triciribine and trastuzumab and methods of use thereof
US20110008327A1 (en)	2004-03-29	2011-01-13	Cheng Jin Q	Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20080213213A1 (en) *	2004-04-14	2008-09-04	Zeldis Jerome B	Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
US20050239867A1 (en) *	2004-04-23	2005-10-27	Zeldis Jerome B	Methods of using and compositions comprising PDE4 modulators for the treatment and management of pulmonary hypertension
WO2005112917A1 (fr) *	2004-05-05	2005-12-01	Celgene Corporation	Procédés d'utilisation et compositions comprenant des médicaments d'inhibition sélective de la cytokine pour le traitement et la gestion de maladies myéloprolifératives
GB0410103D0 (en) *	2004-05-06	2004-06-09	Biolipox Ab	New method
WO2005108353A2 (fr) *	2004-05-06	2005-11-17	Ceptor Corporation	Composes destines a traiter des maladies neurologiques, des maladies otologiques ou des maladies ophtalmologiques et leurs methodes d'utilisation
US20070190070A1 (en) *	2004-09-03	2007-08-16	Zeldis Jerome B	Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
CA2590903A1 (fr) *	2004-12-13	2006-06-22	Celgene Corporation	Preparations incluant des modulateurs de l'activite de pde4 et leur emploi dans le traitement prophylactique ou therapeutique d'inflammations des voies respiratoires
CA2823088C (fr) *	2005-06-30	2015-10-06	Celgene Corporation	Elaboration de composes 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dioniques
US20080138295A1 (en) *	2005-09-12	2008-06-12	Celgene Coporation	Bechet's disease using cyclopropyl-N-carboxamide
RU2008122978A (ru)	2005-11-09	2009-12-20	Комбинаторкс, Инкорпорейтед (Us)	Способы, композиции и наборы для лечения медицинских состояний
CN1870631B (zh) *	2005-11-11	2010-04-14	华为技术有限公司	媒体网关的门控方法
US20070155791A1 (en) *	2005-12-29	2007-07-05	Zeldis Jerome B	Methods for treating cutaneous lupus using aminoisoindoline compounds
US20080103086A1 (en) *	2006-10-25	2008-05-01	Jeon-Soo Shin	Methods for the treatment of diseases associated with the secretion of hmgb1
CA2694987A1 (fr) *	2007-07-17	2009-01-22	Combinatorx, Incorporated	Combinaisons pour le traitement des troubles proliferatifs des lymphocytes b
CA2694983A1 (fr) *	2007-07-17	2009-01-22	Combinatorx, Incorporated	Traitements de troubles proliferatifs des lymphocytes b
US20090081173A1 (en) *	2007-08-10	2009-03-26	The Board Of Regents Of The University Of Texas System	Methods and compositions involving bacteriophage isolates
JP2011515469A (ja) *	2008-03-24	2011-05-19	セルジーンコーポレイション	シクロプロピル−ｎ−｛２−［（１ｓ）−１−（３−エトキシ−４−メトキシフェニル）−２−（メチルスルホニル）エチル］−３−オキソイソインドリン−４−イル｝カルボキサミドを使用した乾癬又は乾癬性関節炎の治療
CN102702070A (zh) *	2008-03-27	2012-10-03	细胞基因公司	包含(+)-2-[1-(3-乙氧基-4-甲氧基苯基)-2-甲基磺酰基乙基]-4-乙酰基氨基异吲哚啉-1,3-二酮的固体形式、其组合物及其用途
EP2687213B1 (fr)	2008-03-27	2019-01-23	Celgene Corporation	Formes solides comprenant de la (+)-2-[1-(3-éthoxy-4-méthoxyphényl)-2-méthylsulfonyléthyl]-4-acétylaminoisoindoline-1,3-dione, leurs compositions, et utilisations associées
HRP20140609T1 (hr)	2008-03-27	2014-08-15	Celgene Corporation	Äśvrsti oblici koji sadrže (+)-2-[1-(3-etoksi-4-metoksifenil)-2-metilsulfoniletil]-4-acetilaminoizoindolin-1,3-dion, njegovi pripravci i njihova upotreba
CN102898349A (zh) *	2008-03-27	2013-01-30	细胞基因公司	包含一种化合物的固体形式、其组合物及其用途
US8053364B2 (en) *	2008-05-01	2011-11-08	Intermolecular, Inc.	Closed-loop sputtering controlled to enhance electrical characteristics in deposited layer
WO2009151569A2 (fr) *	2008-06-09	2009-12-17	Combinatorx, Incorporated	Agonistes des récepteurs bêta-adrénergiques utilisables pour le traitement des troubles prolifératifs des lymphocytes b
WO2010025199A1 (fr) *	2008-09-01	2010-03-04	Mitsubishi Digital Electronics America, Inc.	Systèmes et procédés pour l'amélioration du visionnage sur un téléviseur
US20100186234A1 (en) *	2009-01-28	2010-07-29	Yehuda Binder	Electric shaver with imaging capability
BRPI1007500A2 (pt)	2009-02-10	2016-02-16	Celgene Corp	métodos de uso e composições que compreendem moduladores de pde4 para tratamento, prevenção e gerenciamento de tuberculose
CN107501290A (zh)	2009-05-14	2017-12-22	天津合美医药科技有限公司	噻吩衍生物
EP3831930A1 (fr) *	2009-07-21	2021-06-09	ABT Holding Company	Utilisation de cellules souches pour réduire l'extravasation des leucocytes
CN102053449A (zh) *	2009-10-28	2011-05-11	中国科学院福建物质结构研究所	一种谷氨酸衍生的手性金属-有机非线性光学材料
CN102053448A (zh) *	2009-10-28	2011-05-11	中国科学院福建物质结构研究所	一种硝基苯胺类手性非线性光学材料
ES2727733T3 (es) *	2009-11-10	2019-10-18	Celgene Corp	Nanosuspensión de un fármaco poco soluble preparada por el proceso de microfluidización
JP5937060B2 (ja)	2010-04-07	2016-06-22	セルジーンコーポレイション	呼吸器ウイルス感染症の治療方法
AU2011268450B2 (en)	2010-06-15	2015-07-16	Amgen (Europe) GmbH	Biomarkers for the treatment of psoriasis
WO2012083153A1 (fr) *	2010-12-16	2012-06-21	Nektar Therapeutics	Composés comprenant une fraction apremilast et contenant un oligomère
US9532977B2 (en)	2010-12-16	2017-01-03	Celgene Corporation	Controlled release oral dosage forms of poorly soluble drugs and uses thereof
EP2651400B2 (fr)	2010-12-16	2023-01-18	Amgen (Europe) GmbH	Formes posologiques pour des médicaments peu solubles administrés par voie orale à libération contrôlée et leurs utilisations
CN103391770A (zh)	2011-01-10	2013-11-13	细胞基因公司	环丙烷羧酸{2-[(1s)-1-(3-乙氧基-4-甲氧基-苯基)-2-甲烷磺酰基-乙基]-3-氧代-2,3-二氢-1h-异吲哚-4-基}-酰胺的口服剂型
MX347928B (es)	2011-01-10	2017-05-19	Celgene Corp	Derivados de fenetilsulfona isoindolina y su uso.
US9045417B2 (en)	2011-01-14	2015-06-02	Celgene Corporation	Isotopologues of isoindole derivatives
JP2014511393A (ja) *	2011-03-07	2014-05-15	セルジーンコーポレイション	イソインドリン化合物を用いた疾患の治療方法
CN103635188B (zh) *	2011-04-28	2017-03-22	细胞基因公司	使用pde4抑制剂用于治疗和控制自身免疫性疾病和炎性疾病的方法和组合物
LT3756650T (lt)	2011-12-27	2025-11-10		(+)-2-[1-(3-etoksi-4-metoksi-fenil)-2-metansulfonil-etil]-4- acetilaminoizoindolin-1,3-diono preparatai
WO2013119607A2 (fr)	2012-02-08	2013-08-15	Celgene Corporation	Formulations à libération modifiée à base de (+)-2-[1-(3-éthoxy-4-méthoxy-phényl)-2-méthanesulfonyl-éthyl]-4-acétyl aminoisoindoline-1,3-dione
AR090100A1 (es)	2012-02-21	2014-10-22	Celgene Corp	Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina
US8981117B2 (en)	2012-09-14	2015-03-17	Celgene Corporation	Processes for the preparation of isoindole compounds and isotopologues thereof
JP2015536991A (ja) *	2012-11-09	2015-12-24	セルジーンコーポレイション	骨量の減少の治療方法
BR112015020584A2 (pt)	2013-03-14	2017-07-18	Celgene Corp	métodos para o tratamento de artrite psoriática usando apremilast
EP3539539B1 (fr) *	2013-06-17	2025-11-05	Amgen (Europe) GmbH	Formulations de comprimés de (+)-2-[1+3-ethoxy-4-méthoxyphényl)-(-2-méthylsulfonyléthyl]-4-acétylaminoisoindoline-1,3-dione
KR101561828B1 (ko)	2013-08-23	2015-10-20	주식회사 아미노로직스	α-아미노산의 라세미화 방법
EP3096749B1 (fr) *	2014-01-24	2019-05-15	Celgene Corporation	Méthodes de traitement de l'obésité à l'aide d'aprémilast
JP2014114308A (ja) *	2014-01-31	2014-06-26	Celgene Corp	（＋）−２−［１−（３−エトキシ−４−メトキシフェニル）−２−メチルスルホニルエチル］−４−アセチルアミノイソインドリン−１，３−ジオンを含む固形物形態、その組成物およびその使用
CN103864670B (zh) *	2014-03-17	2015-08-26	苏州明锐医药科技有限公司	阿普司特的制备方法
IN2014MU01283A (fr)	2014-04-04	2015-10-09	Cadila Healthcare Ltd
EP3143004B1 (fr)	2014-05-11	2020-09-02	Mapi Pharma Limited	Forme amorphe d'aprémilast
WO2015175251A1 (fr)	2014-05-12	2015-11-19	Summit Mining International Inc.	Procédé de lixiviation de saumure pour la récupération de métaux de valeur à partir de matériaux oxydés
EP3142748B1 (fr)	2014-05-15	2019-09-11	Celgene Corporation	Utilisation d'inhibiteurs de pde4 et de leurs combinaisons pour le traitement de la fibrose kystique
EP3142663A1 (fr)	2014-05-16	2017-03-22	Celgene Corporation	Compositions et procédés de traitement de maladies cardiovasculaires athérosclérotiques à l'aide de modulateurs de pde4
EP2949645A1 (fr)	2014-05-28	2015-12-02	LEK Pharmaceuticals d.d.	Procédés de préparation de composés ß-aminosulfone
ES2749433T3 (es)	2014-06-23	2020-03-20	Celgene Corp	Apremilast para el tratamiento de una enfermedad hepática o una anomalía de la función hepática
CN105294534B (zh) *	2014-07-15	2020-04-10	上海优拓医药科技有限公司	制备阿普司特及其中间体的产业化方法
WO2016016824A1 (fr)	2014-07-29	2016-02-04	Fundacio Hospital Universitari Vall D' Hebron-Institut De Recerca	Diagnostic différentiel et choix de thérapie pour la polyarthrite rhumatoïde et l'arthrite psoriasique
US10092541B2 (en)	2014-08-15	2018-10-09	Celgene Corporation	Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
CN105622380B (zh) *	2014-10-29	2020-06-30	南京安源生物医药科技有限公司	一种阿普斯特的制备方法及其中间体
CN105588886B (zh) *	2014-11-18	2020-01-31	重庆医药工业研究院有限责任公司	一种采用液相色谱法测定阿普斯特及其制剂中杂质的方法
EP3034496A1 (fr)	2014-12-18	2016-06-22	LEK Pharmaceuticals d.d.	Nouveaux solvates de n-[2-[(1s)-1-(3-ethoxy-4-méthoxyphényl)-2-(méthylsulfonyl)éthyl]-2,3-dihydro-1,3-dioxo-1h-isoindol-4-yl] acétamide
CN104529869B (zh) *	2014-12-19	2017-06-13	苏州亚宝药物研发有限公司	一种 (s)‑2‑[1‑(3‑乙氧基‑4‑甲氧基苯基)‑2‑甲磺酰基乙基]‑4‑乙酰基氨基异吲哚啉‑1,3‑二酮异构体的制备方法
WO2016135755A1 (fr)	2015-02-27	2016-09-01	Mylan Laboratories Limited	Aprémilast amorphe, pré-mélanges correspondant et nouvelles formes cristallines d'aprémilast
CN104803906A (zh) *	2015-03-17	2015-07-29	南京新伟方医药科技有限公司	化合物及其制备方法和用途
US10287248B2 (en)	2015-03-19	2019-05-14	Cipla Limited	Process for the preparation of apremilast
EP3280701B1 (fr)	2015-04-09	2019-10-16	Zentiva K.S.	Procédé de résolution chirale de l'intermédiaire clé de la synthèse d'aprémilast et son utilisation pour la préparation d'aprémilast pur
CN106146384B (zh) *	2015-04-23	2020-09-22	石药集团中奇制药技术（石家庄）有限公司	一种高光学纯度的阿普司特的制备方法、所得产品及其应用
EP3286168A1 (fr)	2015-04-24	2018-02-28	Zentiva K.S.	Forme solide d'aprémilast et un procédé pour sa préparation
WO2016174685A1 (fr)	2015-04-27	2016-11-03	Mylan Laboratories Limited	Procédé de résolution énantiomérique d'intermédiaires d'aprémilast
CN104945306B (zh) *	2015-05-25	2017-07-21	山东铭康医药技术有限公司	制备光学纯阿普斯特的方法
MX2017015151A (es)	2015-05-26	2018-08-15	Lupin Ltd	Un proceso mejorado para la preparación de apremilast y novedosos polimorfos del mismo.
CZ2015383A3 (cs)	2015-06-05	2016-12-14	Zentiva, K.S.	Způsob přípravy klíčového intermediátu apremilastu, využívající enzymatické štěpení racemických aminů
EP3106457A1 (fr)	2015-06-15	2016-12-21	LEK Pharmaceuticals d.d.	Nouvelle voie synthetique vers l'apremilast
CN105111127B (zh) *	2015-08-20	2019-02-19	济南纽华医药科技有限公司	阿普斯特无定形及其制备方法
WO2017033116A1 (fr)	2015-08-26	2017-03-02	Glenmark Pharmaceuticals Limited	Procédé de préparation d'aprémilast
WO2017033206A2 (fr)	2015-08-27	2017-03-02	Msn Laboratories Private Limited	Formes à l'état solide de n-[2-[(1 s)-1 -(3-éthoxy-4-méthoxyphényl)-2-(méthyl sulfonyl)éthyl]-2,3-dihydro-1,3-dioxo-l h-isoindol-4-yl]acétamide et procédé de préparation associé
US9765026B2 (en)	2015-08-28	2017-09-19	Scinopharm Taiwan, Ltd.	Forms of apremilast and the process of making the same
EP3144393A1 (fr)	2015-09-18	2017-03-22	LEK Pharmaceuticals d.d.	Voie synthétique vers l'apremilast
WO2017059040A1 (fr) *	2015-09-29	2017-04-06	Pliva Hrvatska D.O.O.	Procédés de préparation d'aprémilast, et ses intermédiaires
CN105218428A (zh) *	2015-10-20	2016-01-06	南京美嘉宁逸医药研究开发有限公司	一种高手性纯度的阿普斯特的制备方法
WO2017070291A1 (fr)	2015-10-21	2017-04-27	Celgene Corporation	Modulateurs de pde4 pour le traitement et la prévention du syndrome inflammatoire de reconstitution immunitaire (iris)
WO2017083348A1 (fr)	2015-11-11	2017-05-18	Celgene Corporation	Formes pharmaceutiques orales à libération contrôlée de médicaments faiblement solubles et leurs utilisations
US10399942B2 (en)	2015-11-19	2019-09-03	Alembic Pharmaceuticals Limited	Process and novel polymorphic form of Apremilast
CN105348172B (zh) *	2015-12-04	2017-11-14	新发药业有限公司	(s)‑1‑(4‑甲氧基‑3‑乙氧基)苯基‑2‑甲磺酰基乙胺的制备及阿普斯特的制备方法
EP3181549A1 (fr)	2015-12-17	2017-06-21	Zaklady Farmaceutyczne Polpharma SA	Procédé de préparation de l'apremilast
CN105486785A (zh) *	2015-12-23	2016-04-13	成都百裕金阁莱药业有限公司	阿普斯特中对映异构体杂质的检测方法
CZ20165A3 (cs)	2016-01-06	2017-07-19	Zentiva, K.S.	Způsoby přípravy amorfního apremilastu
WO2017179065A1 (fr)	2016-04-15	2017-10-19	Davuluri Ramamohan Rao	Procédé amélioré pour la préparation d'aprémilast
EP3455209A1 (fr)	2016-05-12	2019-03-20	Zaklady Farmaceutyczne Polpharma SA	Formes cristallines de l'aprémilast
WO2017216738A1 (fr)	2016-06-15	2017-12-21	Torrent Pharmaceuticals Limited	Compositions topiques d'apremilast
US10196355B2 (en)	2016-06-20	2019-02-05	Johnson Matthey Public Limited Company	Forms of apremilast
CN106187857B (zh)	2016-06-30	2021-04-06	浙江华海药业股份有限公司	一种制备阿普斯特的方法
IT201600083132A1 (it) *	2016-08-05	2018-02-05	Dipharma Francis Srl	Procedimento per la preparazione di un inibitore della fosfodiesterasi 4
WO2018086473A1 (fr) *	2016-11-09	2018-05-17	广东东阳光药业有限公司	Eutectique d'aprémilast et son procédé de préparation
EP3339292A1 (fr)	2016-12-23	2018-06-27	Zaklady Farmaceutyczne Polpharma SA	Co-cristaux d'apremilast
EA201991790A1 (ru) *	2017-01-27	2020-04-03	Сарудбхава Формулатионс Привате Лимитед	Терапевтические препараты апремиласта для местного применения
CN107445875A (zh) *	2017-03-22	2017-12-08	陕西科技大学	一种用于制备阿普斯特的高纯度中间体的手性拆分方法
EP3606908B1 (fr) *	2017-04-04	2020-06-17	Quimica Sintetica, S.A.	Résolution de composés beta-aminosulfone racémiques
WO2018203192A1 (fr)	2017-05-04	2018-11-08	Unichem Laboratories Ltd	Nouveau procédé de préparation de n-[2-[(1s)-1-(3-éthoxy-4-méthoxyphényl)-2-(méthylsulfonyl)éthyl]-1,3-dioxo-2,3-dihydro-1h-isoindol-4-yl]acétamide
BR112020005077A2 (pt)	2017-09-14	2020-09-15	Glaxosmithkline Intellectual Property Development Limited	tratamento de combinação para câncer
CN107721902A (zh) *	2017-11-08	2018-02-23	中国科学院上海药物研究所	阿普斯特与烟酰胺的共结晶及其制备方法和应用
CN111821299A (zh) *	2019-04-16	2020-10-27	天津合美医药科技有限公司	噻吩衍生物用于治疗免疫球蛋白E（IgE）介导的疾病的应用
CN111821297A (zh) *	2019-04-16	2020-10-27	天津合美医药科技有限公司	异吲哚啉衍生物用于治疗免疫球蛋白E（IgE）介导的疾病的应用
US11357775B2 (en) *	2019-04-30	2022-06-14	Celgene Corporation	Combination therapies comprising apremilast and Tyk2 inhibitors
WO2020222773A1 (fr)	2019-04-30	2020-11-05	Celgene Corporation	Polythérapies comprenant de l'aprémilast et des inhibiteurs de tyk2
CN113169982B (zh) *	2019-08-08	2022-11-29	谷歌有限责任公司	用于内容准个性化的低熵浏览历史
US11194866B2 (en) *	2019-08-08	2021-12-07	Google Llc	Low entropy browsing history for content quasi-personalization
TWI733294B (zh) *	2019-12-30	2021-07-11	國立臺灣師範大學	製備阿普斯特片之方法
CN115397819A (zh) *	2020-02-24	2022-11-25	苏州隆博泰药业有限公司	Pde4抑制剂化合物及其医药用途
EP3929179A1 (fr)	2020-06-22	2021-12-29	Biohorm, S.L.	Composés anti-inflammatoires et leurs procédés de fabrication
CN112220785B (zh) *	2020-09-22	2021-12-31	北京鑫开元医药科技有限公司	一种pde4抑制剂药物组合物及其制备方法与用途
KR20220047105A (ko)	2020-10-08	2022-04-15	주식회사 엔비피헬스케어	아프레밀라스트를 함유하는 약학 조성물
AU2021402911A1 (en) *	2020-12-14	2023-07-06	Biotheryx, Inc.	Pde4 degraders, pharmaceutical compositions, and therapeutic applications
CN115068467A (zh) *	2021-03-15	2022-09-20	中国医学科学院药物研究所	穿心莲内酯作为ltb4受体抑制剂的医药用途
CN114790164B (zh)	2021-08-13	2022-12-27	苏州璞正医药有限公司	一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途
EP4183389A1 (fr)	2021-11-18	2023-05-24	KRKA, d.d., Novo mesto	Composition pharmaceutique comprenant de l'aprémilast
WO2023105286A1 (fr)	2021-12-06	2023-06-15	My Personal Therapeutics Ltd	Polythérapie contre le cancer
AU2021479711A1 (en) *	2021-12-23	2024-06-13	Amgen Inc.	Oral suspension of apremilast
GB202306663D0 (en)	2023-05-05	2023-06-21	Union Therapeutics As	Combination therapy

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US366515A (en)		1887-07-12		Stove-pipe
US3031450A (en)	1959-04-30	1962-04-24	Thomae Gmbh Dr K	Substituted pyrimido-[5, 4-d]-pyrimidines
US3322755A (en)	1964-03-10	1967-05-30	Boehringer Sohn Ingelheim	Basic-substituted 1, 2, 3, 4-tetrahydropyrimido [5, 4-d]-pyrimidines
US3536809A (en)	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
JPS536156B2 (fr)	1972-10-30	1978-03-04
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US3820636A (en) *	1973-08-16	1974-06-28	Deere & Co	Self-adjusting control linkage for an external band brake
US4162316A (en)	1975-03-12	1979-07-24	Dainippon Pharmaceutical Co., Ltd.	1-Substituted-4-(1,2-diphenylethyl)piperazine derivatives and compositions containing the same
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
US4001237A (en)	1976-02-18	1977-01-04	Bristol-Myers Company	Oxazole, isoxazole, thiazole and isothiazole amides
US4060615A (en)	1976-02-18	1977-11-29	Mead Johnson & Company	2-Piperazinyl-6,7-dimethoxyquinazolines
US4001238A (en)	1976-02-18	1977-01-04	Bristol-Myers Company	1,3,4-oxadiazole amides
US4047404A (en)	1976-11-17	1977-09-13	Tanno Senshoku Kogyo Co., Ltd.	Printed fabric washing apparatus
US4101548A (en)	1977-02-22	1978-07-18	Bristol-Myers Company	1,2,3-Thiadiazole amides
US4209623A (en)	1978-06-07	1980-06-24	Bristol-Myers Company	Pyrimidine-5-N-(1H-tetrazol-5-yl)-carboxamides
GB2063249A (en)	1979-10-09	1981-06-03	Mitsubishi Yuka Pharma	4-Phenylphthalazine derivatives
IE58110B1 (en)	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
US4912205A (en)	1986-03-20	1990-03-27	Daicel Chemical Industries, Ltd.	Alkyl-substituted phenylcarbamate derivative of polysaccharide
ATE63553T1 (de)	1986-08-21	1991-06-15	Pfizer	Chinazolindione und pyridopyrimidindione.
CA1303037C (fr)	1987-02-02	1992-06-09	Smith Kline & French Laboratories Limited	Derives de purinone utilises comme bronchodilatateurs,vasodilatateurs et agents anti-allergiques
EP0347146B1 (fr)	1988-06-16	1993-09-01	Smith Kline & French Laboratories Limited	Dérivés de pyrimidine condensés, procédé et intermédiaires pour leur préparation et compositions pharmaceutiques les contenant
GB8814352D0 (en)	1988-06-16	1988-07-20	Smith Kline French Lab	Chemical compounds
US5075310A (en)	1988-07-01	1991-12-24	Smith Kline & French Laboratories, Ltd.	Pyrimidone derivatives as bronchodilators
US5073543A (en)	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8817651D0 (en)	1988-07-25	1988-09-01	Smith Kline French Lab	Chemical compounds
GB8827988D0 (en)	1988-11-30	1989-01-05	Smith Kline French Lab	Chemical compounds
IT1229203B (it)	1989-03-22	1991-07-25	Bioresearch Spa	Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
GB8909560D0 (en)	1989-04-26	1989-06-14	Smith Kline French Lab	Chemical compounds
GB8923131D0 (en)	1989-10-13	1989-11-29	Smith Kline French Lab	Chemical compounds
US5120548A (en)	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
US5733566A (en)	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
GB9013750D0 (en)	1990-06-20	1990-08-08	Pfizer Ltd	Therapeutic agents
US5401774A (en)	1991-03-08	1995-03-28	University Of Arizona	Method for treating patients with precancerous lesions by administering substituted sulfonyl idenyl acetic and propionic acids and esters to patients with lesions sensitive to such compounds
GB9114760D0 (en)	1991-07-09	1991-08-28	Pfizer Ltd	Therapeutic agents
PT100905A (pt)	1991-09-30	1994-02-28	Eisai Co Ltd	Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
GB9121028D0 (en)	1991-10-03	1991-11-13	Pfizer Ltd	Therapeutic agents
GB9126260D0 (en)	1991-12-11	1992-02-12	Pfizer Ltd	Therapeutic agents
US5580578A (en)	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5354571A (en)	1992-04-27	1994-10-11	Rheon Automatic Machinery Co., Ltd.	Method for aligning and bending individual round elongated dough pieces
US5243826A (en)	1992-07-01	1993-09-14	Apd Cryogenics Inc.	Method and apparatus for collecting liquid cryogen
JP2657760B2 (ja)	1992-07-15	1997-09-24	小野薬品工業株式会社	４−アミノキナゾリン誘導体およびそれを含有する医薬品
GB9218322D0 (en)	1992-08-28	1992-10-14	Pfizer Ltd	Therapeutic agents
US5591767A (en)	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
GB9312210D0 (en)	1993-06-14	1993-07-28	Smithkline Beecham Plc	Chemical compounds
US5698579A (en)	1993-07-02	1997-12-16	Celgene Corporation	Cyclic amides
CA2148260A1 (fr)	1993-09-10	1995-03-16	Yasutaka Takase	Composes a base de quinazoline
GB9514465D0 (en)	1995-07-14	1995-09-13	Glaxo Lab Sa	Chemical compounds
GB9401090D0 (en)	1994-01-21	1994-03-16	Glaxo Lab Sa	Chemical compounds
IT1270594B (it)	1994-07-07	1997-05-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5608914A (en)	1994-11-21	1997-03-11	Keesler; Daren	Headcover
GB9423910D0 (en)	1994-11-26	1995-01-11	Pfizer Ltd	Therapeutic agents
US5801195A (en)	1994-12-30	1998-09-01	Celgene Corporation	Immunotherapeutic aryl amides
US5703098A (en)	1994-12-30	1997-12-30	Celgene Corporation	Immunotherapeutic imides/amides
DE19501482A1 (de)	1995-01-19	1996-07-25	Bayer Ag	2,9-disubstituierte Purin-6-one
DE19501481A1 (de)	1995-01-19	1996-07-25	Bayer Ag	2,8-Disubstituierte Chinazolinone
DE19501480A1 (de)	1995-01-19	1996-07-25	Bayer Ag	9-substituierte 2-(2-n-Alkoxyphenyl)-purin-6-one
US5614530A (en)	1995-03-10	1997-03-25	Sterling Winthrop Inc.	Substituted N-arylmethyl and heterocyclmethyl-1H-pyrazolo[3,4-b]quinolin-4-amines and compositions and methods of use thereof
US5488055A (en)	1995-03-10	1996-01-30	Sanofi Winthrop Inc.	Substituted N-cycloalkylmethyl-1H-pyrazolo(3,4-b)quinolin-4 amines and compositions and methods of use thereof
ATE219765T1 (de)	1995-04-10	2002-07-15	Fujisawa Pharmaceutical Co	Indolderivate als cgmp-pde inhibitoren
TW381092B (en)	1995-07-07	2000-02-01	Otsuka Pharma Co Ltd	Novel benzimidazole derivatives for use in treating arteriosclerotic diseases
GB9514473D0 (en)	1995-07-14	1995-09-13	Glaxo Lab Sa	Chemical compounds
GB9514464D0 (en)	1995-07-14	1995-09-13	Glaxo Lab Sa	Medicaments
US5728844A (en)	1995-08-29	1998-03-17	Celgene Corporation	Immunotherapeutic agents
US5728845A (en)	1995-08-29	1998-03-17	Celgene Corporation	Immunotherapeutic nitriles
US5736537A (en)	1995-09-12	1998-04-07	Estee Lauder, Inc.	Dehydroep:androsterone sailcylate useful against skin atrophy
US5658940A (en)	1995-10-06	1997-08-19	Celgene Corporation	Succinimide and maleimide cytokine inhibitors
US6166041A (en)	1995-10-11	2000-12-26	Euro-Celtique, S.A.	2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
DE19540475A1 (de)	1995-10-20	1997-04-24	Schering Ag	Chirale Methylphenyloxazolidinone
US5710170A (en)	1995-12-15	1998-01-20	Merck Frosst Canada, Inc.	Tri-aryl ethane derivatives as PDE IV inhibitors
GB9526245D0 (en)	1995-12-21	1996-02-21	Celltech Therapeutics Ltd	Chemical compounds
GB9526246D0 (en)	1995-12-21	1996-02-21	Celltech Therapeutics Ltd	Chemical compounds
GB9526243D0 (en)	1995-12-21	1996-02-21	Celltech Therapeutics Ltd	Chemical compounds
DE69635135T2 (de)	1995-12-28	2006-07-06	Fujisawa Pharmaceutical Co., Ltd.	Benzimidazolderivate
GB9604926D0 (en)	1996-03-08	1996-05-08	Sandoz Ltd	Organic compounds
DE19617864A1 (de)	1996-04-23	1997-10-30	Schering Ag	Neue chirale Phenyldihydrofuranone
DE19632423A1 (de)	1996-08-12	1998-02-19	Merck Patent Gmbh	Thienopyrimidine
CA2236012A1 (fr)	1996-08-30	1998-03-05	Koji Yamada	Derives d'imidazoquinazoline
ES2187814T3 (es)	1996-10-04	2003-06-16	Kyorin Seiyaku Kk	Derivados de pirazolopiridinopiridazinonas y procedimiento para su preparacion.
DE19642451A1 (de)	1996-10-15	1998-04-16	Merck Patent Gmbh	Aminothiophencarbonsäureamide
DE19644228A1 (de)	1996-10-24	1998-04-30	Merck Patent Gmbh	Thienopyrimidine
KR100239800B1 (ko)	1996-11-28	2000-03-02	손경식	4,5-디아미노 피리미딘 유도체 및 이의 제조방법
WO1998038168A1 (fr)	1997-02-27	1998-09-03	Tanabe Seiyaku Co., Ltd.	Derives d'isoquinolinone, procede de preparation desdits derives et leur utilisation en tant qu'inhibiteurs de phosphodiesterase
ATE386531T1 (de)	1997-02-28	2008-03-15	Nycomed Gmbh	Synergistische kombination von pde-hemmern und adenylatcyclase-agonisten bzw. guanylcyclyse- agonisten
US6035089A (en) *	1997-06-11	2000-03-07	Lockheed Martin Energy Research Corporation	Integrated narrowband optical filter based on embedded subwavelength resonant grating structures
RU2199530C2 (ru)	1997-07-31	2003-02-27	Селджин Корпорейшн	ЗАМЕЩЕННЫЕ ГИДРОКСАМОВЫЕ КИСЛОТЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ СНИЖЕНИЯ УРОВНЕЙ TNFα
US6020339A (en)	1997-10-03	2000-02-01	Merck & Co., Inc.	Aryl furan derivatives as PDE IV inhibitors
US6034089A (en)	1997-10-03	2000-03-07	Merck & Co., Inc.	Aryl thiophene derivatives as PDE IV inhibitors
CA2299399C (fr)	1997-11-25	2004-04-06	Warner-Lambert Company	Inhibiteurs benzenesulfamides de la phosphodiesterase iv et utilisation therapeutique de ces derniers
US6020358A (en)	1998-10-30	2000-02-01	Celgene Corporation	Substituted phenethylsulfones and method of reducing TNFα levels
US6025394A (en)	1999-01-29	2000-02-15	Cell Pathways, Inc.	Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
AU764005B2 (en)	1999-02-25	2003-08-07	Merck Frosst Canada & Co.	PDE IV inhibiting compounds, compositions and methods of treatment
US6316472B1 (en)	1999-05-13	2001-11-13	Merck Frosst Canada & Co.	Heterosubstituted pyridine derivatives as PDE 4 inhibitors
US6667316B1 (en) *	1999-11-12	2003-12-23	Celgene Corporation	Pharmaceutically active isoindoline derivatives
SE9904415D0 (sv)	1999-12-03	1999-12-03	Astra Ab	New process
ATE290002T1 (de) *	1999-12-23	2005-03-15	Icos Corp	Cyclische amp spezifische phosphodiesterase inhibitoren
US7354941B2 (en)	2000-01-31	2008-04-08	Pfizer Products Inc.	Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of PDE4 isozymes
US6962940B2 (en) *	2002-03-20	2005-11-08	Celgene Corporation	(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en)	2002-03-20	2011-02-22	Celgene Corporation	Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7276529B2 (en) *	2002-03-20	2007-10-02	Celgene Corporation	Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7208516B2 (en) *	2002-03-20	2007-04-24	Celgene Corporation	Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7123975B2 (en) *	2004-07-22	2006-10-17	Taiwan Semiconductor Manufacturing Co., Ltd.	Manufacturing management system and method
WO2008063213A2 (fr)	2006-04-10	2008-05-29	Abbott Biotechnology Ltd.	Compositions destinées au traitement de la polyarthrite psoriasique et leurs applications
KR100988184B1 (ko)	2007-07-19	2010-10-18	세키스이가가쿠 고교가부시키가이샤	전자 부품용 접착제
DK2250161T3 (da)	2008-01-18	2014-01-27	Atopix Therapeutics Ltd	Forbindelser med CRTH2-antagonistaktivitet
HRP20140609T1 (hr)	2008-03-27	2014-08-15	Celgene Corporation	Äśvrsti oblici koji sadrže (+)-2-[1-(3-etoksi-4-metoksifenil)-2-metilsulfoniletil]-4-acetilaminoizoindolin-1,3-dion, njegovi pripravci i njihova upotreba
MX2012004741A (es)	2009-11-19	2012-05-22	Celgene Corp	Apremilast para el tratamiento de sarcoidosis.
WO2011151372A1 (fr)	2010-06-02	2011-12-08	Ab Science	Traitement de l'arthrite rhumatoïde par du masitinib

2003
- 2003-03-19 US US10/392,195 patent/US6962940B2/en not_active Expired - Lifetime
- 2003-03-20 HU HUE15177140A patent/HUE043539T2/hu unknown
- 2003-03-20 WO PCT/US2003/008738 patent/WO2003080049A1/fr not_active Ceased
- 2003-03-20 PT PT101626539T patent/PT2223687T/pt unknown
- 2003-03-20 KR KR1020107003988A patent/KR101104991B1/ko not_active Expired - Lifetime
- 2003-03-20 CA CA2479666A patent/CA2479666C/fr not_active Expired - Fee Related
- 2003-03-20 EP EP10186076.5A patent/EP2311453B1/fr not_active Expired - Lifetime
- 2003-03-20 MX MX2015010082A patent/MX366328B/es unknown
- 2003-03-20 PT PT15177140T patent/PT2962690T/pt unknown
- 2003-03-20 SI SI200332539T patent/SI2295055T1/sl unknown
- 2003-03-20 EP EP10186086.4A patent/EP2295055B1/fr not_active Expired - Lifetime
- 2003-03-20 PT PT10162667T patent/PT2223688T/pt unknown
- 2003-03-20 SI SI200332591T patent/SI2962690T1/sl unknown
- 2003-03-20 MX MXPA04009075A patent/MXPA04009075A/es active IP Right Grant
- 2003-03-20 ES ES11176719.0T patent/ES2595375T3/es not_active Expired - Lifetime
- 2003-03-20 ES ES10186076.5T patent/ES2637547T3/es not_active Expired - Lifetime
- 2003-03-20 SI SI200332599T patent/SI2223688T1/sl unknown
- 2003-03-20 EP EP03721414A patent/EP1485087B1/fr not_active Revoked
- 2003-03-20 JP JP2003577877A patent/JP2005525386A/ja active Pending
- 2003-03-20 DK DK10186086.4T patent/DK2295055T3/en active
- 2003-03-20 ES ES09003138.6T patent/ES2608495T3/es not_active Expired - Lifetime
- 2003-03-20 PT PT111767190T patent/PT2420490T/pt unknown
- 2003-03-20 ES ES15177140T patent/ES2717517T3/es not_active Expired - Lifetime
- 2003-03-20 CA CA2756798A patent/CA2756798A1/fr not_active Abandoned
- 2003-03-20 SI SI200332535T patent/SI2223687T1/sl unknown
- 2003-03-20 ES ES03721414T patent/ES2331991T3/es not_active Expired - Lifetime
- 2003-03-20 EP EP19151685.5A patent/EP3524242A1/fr not_active Withdrawn
- 2003-03-20 ES ES10162667T patent/ES2742729T3/es not_active Expired - Lifetime
- 2003-03-20 ES ES10186086.4T patent/ES2637509T3/es not_active Expired - Lifetime
- 2003-03-20 PT PT03721414T patent/PT1485087E/pt unknown
- 2003-03-20 KR KR1020047015190A patent/KR100997001B1/ko not_active Ceased
- 2003-03-20 DE DE60328974T patent/DE60328974D1/de not_active Expired - Lifetime
- 2003-03-20 IL IL16414703A patent/IL164147A0/xx unknown
- 2003-03-20 HU HUE10186086A patent/HUE034348T2/hu unknown
- 2003-03-20 CN CNB038110938A patent/CN100427085C/zh not_active Expired - Lifetime
- 2003-03-20 KR KR1020137021411A patent/KR20130100219A/ko not_active Ceased
- 2003-03-20 DK DK03721414T patent/DK1485087T3/da active
- 2003-03-20 NZ NZ535798A patent/NZ535798A/en not_active IP Right Cessation
- 2003-03-20 HU HUE11176719A patent/HUE029682T2/en unknown
- 2003-03-20 KR KR1020127000230A patent/KR101263786B1/ko not_active Expired - Lifetime
- 2003-03-20 CN CN200910181158A patent/CN101683334A/zh active Pending
- 2003-03-20 EP EP10162667.9A patent/EP2223688B1/fr not_active Revoked
- 2003-03-20 EP EP10162653.9A patent/EP2223687B1/fr not_active Revoked
- 2003-03-20 DK DK10162667.9T patent/DK2223688T3/da active
- 2003-03-20 KR KR1020137004997A patent/KR101383845B1/ko not_active Expired - Lifetime
- 2003-03-20 PT PT101860864T patent/PT2295055T/pt unknown
- 2003-03-20 DK DK15177140.9T patent/DK2962690T3/en active
- 2003-03-20 ES ES10162653.9T patent/ES2635361T3/es not_active Expired - Lifetime
- 2003-03-20 DK DK10162653.9T patent/DK2223687T3/en active
- 2003-03-20 EP EP11176719.0A patent/EP2420490B1/fr not_active Expired - Lifetime
- 2003-03-20 HU HUE10162667A patent/HUE045489T2/hu unknown
- 2003-03-20 KR KR1020117003333A patent/KR20110022736A/ko not_active Ceased
- 2003-03-20 AU AU2003224729A patent/AU2003224729C1/en active Active
- 2003-03-20 DK DK11176719.0T patent/DK2420490T3/en active
- 2003-03-20 AT AT03721414T patent/ATE440599T1/de active
- 2003-03-20 EP EP09003138.6A patent/EP2074995B1/fr not_active Revoked
- 2003-03-20 EP EP15177140.9A patent/EP2962690B1/fr not_active Revoked
- 2003-03-20 SI SI200331659T patent/SI1485087T1/sl unknown
2004
- 2004-09-20 IL IL164147A patent/IL164147A/en active Protection Beyond IP Right Term
2005
- 2005-04-13 US US11/106,142 patent/US7427638B2/en active Active
- 2005-06-28 US US11/170,308 patent/US7358272B2/en not_active Expired - Lifetime
2007
- 2007-06-29 US US11/824,523 patent/US7507759B2/en not_active Expired - Lifetime
2008
- 2008-02-08 US US12/069,282 patent/US7659302B2/en not_active Expired - Lifetime
- 2008-04-04 US US12/098,379 patent/US7659303B2/en not_active Expired - Lifetime
2009
- 2009-09-18 CY CY20091100967T patent/CY1109380T1/el unknown
- 2009-12-03 US US12/630,788 patent/US8455536B2/en not_active Expired - Fee Related
- 2009-12-28 JP JP2009297650A patent/JP2010106033A/ja active Pending
2010
- 2010-07-22 IL IL207149A patent/IL207149A/en active IP Right Review Request
2012
- 2012-11-02 JP JP2012242868A patent/JP5936521B2/ja not_active Expired - Lifetime
- 2012-11-20 US US13/682,652 patent/US8802717B2/en not_active Expired - Lifetime
2014
- 2014-06-26 US US14/316,160 patent/US9283207B2/en not_active Expired - Fee Related
- 2014-09-18 JP JP2014190477A patent/JP2015013893A/ja active Pending
2016
- 2016-02-05 US US15/016,856 patent/US9724330B2/en not_active Expired - Fee Related
2017
- 2017-06-21 US US15/629,678 patent/US10092542B2/en not_active Expired - Lifetime
- 2017-07-14 CY CY20171100748T patent/CY1119204T1/el unknown
- 2017-08-21 CY CY20171100884T patent/CY1119340T1/el unknown
2018
- 2018-09-07 US US16/125,571 patent/US10610516B2/en not_active Expired - Fee Related
2019
- 2019-04-03 CY CY20191100372T patent/CY1121720T1/el unknown
- 2019-06-14 LU LU00125C patent/LUC00125I2/fr unknown
- 2019-06-18 HU HUS1900032C patent/HUS1900032I1/hu unknown
- 2019-06-18 BE BE2019C008C patent/BE2019C008I2/nl unknown
- 2019-06-18 CY CY2019032C patent/CY2019032I2/el unknown
- 2019-06-18 NL NL300994C patent/NL300994I2/nl unknown
- 2019-07-12 FR FR19C1046C patent/FR19C1046I2/fr active Active
- 2019-08-14 CY CY20191100877T patent/CY1121888T1/el unknown
2020
- 2020-02-28 US US16/805,196 patent/US11040024B2/en not_active Expired - Fee Related
- 2020-08-26 US US17/003,238 patent/US11260046B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US10092542B2 (en)	2018-10-09
US20200306226A1 (en)	2020-10-01
ES2717517T3 (es)	2019-06-21
FR19C1046I2 (fr)	2022-07-08
NL300994I2 (nl)	2019-07-11
ES2637509T3 (es)	2017-10-13
AU2003224729C9 (en)	2023-06-15
PT1485087E (pt)	2009-10-23
AU2003224729A1 (en)	2003-10-08
US8802717B2 (en)	2014-08-12
US20210023051A1 (en)	2021-01-28
LUC00125I2 (fr)	2019-12-24
DK2420490T3 (en)	2016-10-03
CA2756798A1 (fr)	2003-10-02
KR20130040257A (ko)	2013-04-23
KR20130100219A (ko)	2013-09-09
US20030187052A1 (en)	2003-10-02
AU2003224729B2 (en)	2008-01-03
EP2420490B1 (fr)	2016-07-20
ATE440599T1 (de)	2009-09-15
MX366328B (es)	2019-07-05
CA2479666C (fr)	2012-01-10
JP5936521B2 (ja)	2016-06-22
US20050267196A1 (en)	2005-12-01
SI1485087T1 (sl)	2009-12-31
JP2005525386A (ja)	2005-08-25
EP2311453A1 (fr)	2011-04-20
ES2608495T3 (es)	2017-04-11
EP2311453B1 (fr)	2017-06-07
US6962940B2 (en)	2005-11-08
US11040024B2 (en)	2021-06-22
KR20100040938A (ko)	2010-04-21
EP1485087A1 (fr)	2004-12-15
HUE029682T2 (en)	2017-02-28
DK2962690T3 (en)	2019-04-15
HK1103985A1 (en)	2008-01-04
CY1109380T1 (el)	2014-07-02
CA2479666A1 (fr)	2003-10-02
EP3524242A1 (fr)	2019-08-14
EP2295055A3 (fr)	2011-03-23
SI2295055T1 (sl)	2017-10-30
PT2420490T (pt)	2016-10-12
US20140371287A1 (en)	2014-12-18
DE60328974D1 (de)	2009-10-08
KR20110022736A (ko)	2011-03-07
CN101683334A (zh)	2010-03-31
DK1485087T3 (da)	2009-11-02
MXPA04009075A (es)	2005-07-13
CN100427085C (zh)	2008-10-22
NL300994I1 (nl)	2019-06-26
PT2223688T (pt)	2019-09-05
KR101383845B1 (ko)	2014-04-10
PT2962690T (pt)	2019-04-30
WO2003080049A1 (fr)	2003-10-02
KR101104991B1 (ko)	2012-01-16
SI2223687T1 (sl)	2017-10-30
US9724330B2 (en)	2017-08-08
US20160151331A1 (en)	2016-06-02
EP2223688A1 (fr)	2010-09-01
HK1219049A1 (en)	2017-03-24
US10610516B2 (en)	2020-04-07
HUE043539T2 (hu)	2019-08-28
PT2295055T (pt)	2017-08-29
HUE045489T2 (hu)	2019-12-30
US7427638B2 (en)	2008-09-23
CN1652772A (zh)	2005-08-10
US7659303B2 (en)	2010-02-09
IL207149A (en)	2013-12-31
HK1073426A1 (en)	2005-10-07
US20140024695A1 (en)	2014-01-23
EP2420490A1 (fr)	2012-02-22
AU2003224729C1 (en)	2025-01-23
EP1485087B1 (fr)	2009-08-26
JP2010106033A (ja)	2010-05-13
CY1121888T1 (el)	2020-10-14
US20050192336A1 (en)	2005-09-01
ES2637547T3 (es)	2017-10-13
DK2295055T3 (en)	2017-09-11
EP2223688B1 (fr)	2019-05-29
SI2962690T1 (sl)	2019-05-31
KR20050012722A (ko)	2005-02-02
EP2962690B1 (fr)	2019-01-16
PT2223687T (pt)	2017-07-25
EP2295055A2 (fr)	2011-03-16
US20190000804A1 (en)	2019-01-03
US7358272B2 (en)	2008-04-15
CY2019032I1 (el)	2020-05-29
EP2223687B1 (fr)	2017-05-17
US20100160405A1 (en)	2010-06-24
LUC00125I1 (fr)	2019-06-18
US7507759B2 (en)	2009-03-24
EP2295055B1 (fr)	2017-06-07
CY1119340T1 (el)	2018-02-14
US8455536B2 (en)	2013-06-04
CY1121720T1 (el)	2020-05-29
CY2019032I2 (el)	2020-05-29
ES2635361T3 (es)	2017-10-03
US20080242719A1 (en)	2008-10-02
ES2742729T3 (es)	2020-02-17
DK2223687T3 (en)	2017-08-14
US11260046B2 (en)	2022-03-01
KR20120024938A (ko)	2012-03-14
EP2962690A1 (fr)	2016-01-06
ES2331991T3 (es)	2010-01-22
US20170281597A1 (en)	2017-10-05
JP2013047262A (ja)	2013-03-07
IL164147A0 (en)	2005-12-18
US7659302B2 (en)	2010-02-09
JP2015013893A (ja)	2015-01-22
IL164147A (en)	2010-11-30
ES2595375T3 (es)	2016-12-29
CY1119204T1 (el)	2018-02-14
EP2223687A1 (fr)	2010-09-01
HUE034348T2 (hu)	2018-02-28
DK2223688T3 (da)	2019-08-19
EP2074995B1 (fr)	2016-11-02
US20080027123A1 (en)	2008-01-31
US9283207B2 (en)	2016-03-15
NZ535798A (en)	2006-04-28
KR101263786B1 (ko)	2013-05-13
SI2223688T1 (sl)	2019-11-29
HUS1900032I1 (hu)	2019-07-29
KR100997001B1 (ko)	2010-11-25
EP2074995A1 (fr)	2009-07-01
BE2019C008I2 (fr)	2022-08-09
US20080207730A1 (en)	2008-08-28

Publication	Publication Date	Title
FR19C1046I2 (fr)	2022-07-08	(+)-2-[1-(3-éthoxy-4-méthoxyphényl)-2-méthylsulfonyléthyl]-4-acétylaminoisoindoline-1,3-dione: ses procédés d'utilisation et compositions correspondantes
EP4516353A3 (fr)	2025-05-21	Compositions pharmaceutiques comprenant du (2s)-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
MXPA05004778A (es)	2005-10-05	Metodos de uso y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades mieloproliferativas.
IL165262A (en)	2011-10-31	Kinase inhibitors and pharmaceutical compositions containing them
MXPA05007609A (es)	2005-09-30	Antagonista de un receptor sensible al calcio.
FR2850023B1 (fr)	2007-04-06	Medicaments pour le systeme nerveux
CO5580741A2 (es)	2005-11-30	Composicion farmaceutica que comprende un agonista de receptor de 5ht1
MXPA06003122A (es)	2006-05-31	Composiciones farmaceuticas y procedimientos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y un agonista/antagonista de estrogenos.
AU2001246999A1 (en)	2001-10-23	New neurokinin antagonists for use as medicaments
SE0302572D0 (sv)	2003-09-26	Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
GB0228552D0 (en)	2003-01-15	Chemical compounds
TW200517127A (en)	2005-06-01	Novel composition
EA200401617A1 (ru)	2005-06-30	Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера
BRPI0409127A (pt)	2006-03-28	combinação farmacêutica compreendendo eletriptano e bicarbonato de sódio
MY137391A (en)	2009-01-30	New process for the synthesis of n-[(s)-1-ethoxycarbonylbutyl]-(s)-alanine and application in the synthesis of perindopril
MY149837A (en)	2013-10-31	New process for the synthesis of perindopril and pharmaceutically acceptable salts thereof
EA200600501A1 (ru)	2006-08-25	Новый способ синтеза сложных эфиров n-[(s)-1-карбоксибутил]-(s)-аланина и их применение для синтеза периндоприла
BRPI0411043A (pt)	2006-07-11	composição medicinal
MY139916A (en)	2009-11-30	Crystalline derivatives of 2-(5-chlorothien-2-yl)-n-((3s)-1((1s)-1-methyl-2-morpholin-4-yl)-2-oxoethyl)-2-oxopyrrolidin-3-yl)ethensulfonamide